CN106729092A - A kind of blood fat reducing preparation containing xylo-oligosaccharide and its preparation method and application - Google Patents
A kind of blood fat reducing preparation containing xylo-oligosaccharide and its preparation method and application Download PDFInfo
- Publication number
- CN106729092A CN106729092A CN201611249047.7A CN201611249047A CN106729092A CN 106729092 A CN106729092 A CN 106729092A CN 201611249047 A CN201611249047 A CN 201611249047A CN 106729092 A CN106729092 A CN 106729092A
- Authority
- CN
- China
- Prior art keywords
- parts
- oligosaccharide
- xylo
- blood fat
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 62
- 239000008280 blood Substances 0.000 title claims abstract description 62
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 26
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 26
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 25
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 25
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 25
- 240000000249 Morus alba Species 0.000 claims abstract description 24
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 24
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 23
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 23
- 244000185386 Thladiantha grosvenorii Species 0.000 claims abstract description 23
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 claims abstract description 23
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 22
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 22
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 22
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 22
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 22
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 22
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 22
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 22
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 22
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 22
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims abstract description 20
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims abstract description 20
- 241000234435 Lilium Species 0.000 claims abstract description 20
- 241000228347 Monascus <ascomycete fungus> Species 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims abstract description 9
- 230000036039 immunity Effects 0.000 claims abstract description 7
- 235000004879 dioscorea Nutrition 0.000 claims abstract description 4
- 235000013312 flour Nutrition 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims abstract description 4
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 6
- 239000000284 extract Substances 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 22
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 19
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 19
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 19
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 229920001503 Glucan Polymers 0.000 claims description 15
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 15
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims description 14
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 9
- 230000036541 health Effects 0.000 claims description 8
- 201000005577 familial hyperlipidemia Diseases 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 241000381602 Vachellia nebrownii Species 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 229940026314 red yeast rice Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 33
- 150000002632 lipids Chemical class 0.000 abstract description 18
- 241000894006 Bacteria Species 0.000 abstract description 8
- 230000035622 drinking Effects 0.000 abstract description 8
- 235000008216 herbs Nutrition 0.000 abstract description 8
- 230000010354 integration Effects 0.000 abstract description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 7
- 239000006041 probiotic Substances 0.000 abstract description 7
- 235000018291 probiotics Nutrition 0.000 abstract description 7
- 230000009467 reduction Effects 0.000 abstract description 6
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 229920001542 oligosaccharide Polymers 0.000 abstract description 5
- 150000002482 oligosaccharides Chemical class 0.000 abstract description 5
- -1 xylo-oligosaccharide Chemical class 0.000 abstract description 4
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 abstract description 2
- 229920002498 Beta-glucan Polymers 0.000 abstract description 2
- 150000001480 arabinoses Chemical class 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 32
- 241001092040 Crataegus Species 0.000 description 16
- 235000012000 cholesterol Nutrition 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 235000013305 food Nutrition 0.000 description 7
- 150000004676 glycans Chemical class 0.000 description 7
- 206010033307 Overweight Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 241000186000 Bifidobacterium Species 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003613 bile acid Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 102000000853 LDL receptors Human genes 0.000 description 2
- 108010001831 LDL receptors Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 2
- 150000004056 anthraquinones Chemical class 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000000055 hyoplipidemic effect Effects 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000001573 invertase Substances 0.000 description 2
- 235000011073 invertase Nutrition 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 description 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002402 anti-lipaemic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- CQIUKKVOEOPUDV-IYSWYEEDSA-N antimycin Chemical compound OC1=C(C(O)=O)C(=O)C(C)=C2[C@H](C)[C@@H](C)OC=C21 CQIUKKVOEOPUDV-IYSWYEEDSA-N 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- CQIUKKVOEOPUDV-UHFFFAOYSA-N citrinine Natural products OC1=C(C(O)=O)C(=O)C(C)=C2C(C)C(C)OC=C21 CQIUKKVOEOPUDV-UHFFFAOYSA-N 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- SYKWLIJQEHRDNH-CKRMAKSASA-N glutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 SYKWLIJQEHRDNH-CKRMAKSASA-N 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000037219 healthy weight Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930189775 mogroside Natural products 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of blood fat reducing preparation containing xylo-oligosaccharide and its application, it is made up of the raw material of following weight portion：11 16 parts of hawthorn, 9 13 parts of oat beta glucan, 8 14 parts of L arabinoses, 7 12 parts of gynostemma pentaphylla, 6 10 parts of Momordica grosvenori, 59 parts of the root of kudzu vine, 6 10 parts of mulberry leaf, 5 10 parts of xylo-oligosaccharide powder, 48 parts of lotus leaf, 37 parts of yam flour, 58 parts of cassia seed, 36 parts of lily, 26 parts of functional Monascus.The present invention passes through scientific compatibility, the Chinese medicinal material of several integration of drinking and medicinal herbs is selected to coordinate the oligosaccharides such as xylo-oligosaccharide, it is made the preparation with reduction blood fat effect, wherein, the oligosaccharides such as the xylo-oligosaccharide of addition give full play to bifidus factor effect, can dramatically increase beneficial bacteria of intestinal tract group's quantity, and coordinating has reducing blood lipid, the integration of drinking and medicinal herbs Chinese medicine of enhance immunity, mitigate influence of the Chinese medicine to gut flora, so as to realize cooperatively being played with probiotics the effect of its reducing blood lipid.
Description
Technical field
The invention belongs to food technology field, and in particular to a kind of containing the blood fat reducing preparation of xylo-oligosaccharide and its preparation side
Method, and in particular to it is a kind of with reduction blood fat and serum cholesterol, regulation blood sugar, increase beneficial bacteria of intestinal tract group, relax bowel
Blood fat reducing preparation and preparation method thereof.
Background technology
Hyperlipemia refers mainly to the protein that same lipid is combined, such as low-density lipoprotein, height also known as hyperlipoprotememia
Density lipoprotein and VLDL etc., predisposing factors are excessive mainly due to the fat content in blood, cause body
There are atherosclerosis, be a kind of disease clinically the most common at present.With the improvement of people's living standard
And raising, hyperlipemia incidence increases substantially.In recent years, the scholar of many countries is carried out to the treatment of hyperlipemia
Research, its treatment is roughly divided into medicine and the major class of non-drug therapy two.High fat of blood can cause serious angiocardiopathy, in utilization
Medicine treatment hyperlipidemia is present more effective method.
The period Tang Dynasty《Huangdi Neijing Taisu, Grand Simplicity of Inner Canon of Huangdi》Write in one book：" food is food on an empty stomach, and patient's food is medicine ", instead
Mirror the thought of " integration of drinking and medicinal herbs ".Integration of drinking and medicinal herbs food hawthorn, Chinese yam, radix polygonati officinalis, cassia seed, Momordica grosvenori, lotus leaf, mulberry leaf etc., product
Matter is natural, also eat also medicine, deep by consumers all over the world the effect of with integration of drinking and medicinal herbs.The Small side effects of food, and medicine
The side effect of thing is big.And medicine-food two-purpose often uses antilipemic Chinese herbal medicine material, the flavonoids organic acid mainly contained based on Hyperoside is effective
Composition.
At present, the chemicals of in the market treatment hyperlipemia is generally Statins and fibrates, although Western medicine curative effect is preferable, but
Effect is single and easily produces adverse reaction, is easily rebounded after drug withdrawal, and recurrence rate is higher, clinically has some limitations.
Traditional Chinese medicine thinks that the hyperlipidemia interpretation of the cause, onset and process of an illness belongs to asthenia in origin and asthenia in superficiality, and predominantly blood stasis, phlegm is turbid, show as more caused by liver and kidney deficiency, insufficiency of the spleen phlegm it is turbid,
Qi depression to blood stasis.But Reducing Blood Lipid by Chinese medicine complicated mechanism, comprehensive function is played often through multicomponent, multipath.The side of taking of Chinese medicine
Method is typically generally oral, and with the oral Chinese medicine of decoction form, its chemical composition is then directly entered alimentary canal, and stimulate digestion wall
Trigger immune activation to produce biological effect, enteral microecological balance may be destroyed, influence beneficial bacteria of intestinal tract group's normal physiological function,
Even trigger some patientss to take the adverse reaction of Chinese drugs agentia, influence therapeutic effect.
The content of the invention
For above-mentioned prior art, to overcome the not enough defect of western medicine composition in the prior art, the invention provides one kind
Blood fat reducing preparation containing xylo-oligosaccharide, it has reduction blood fat and serum cholesterol, regulation blood sugar, increases beneficial bacteria of intestinal tract group,
Reach integration of drinking and medicinal herbs raw material and cooperatively play the effect of reducing blood lipid with probiotics.
One object of the present invention provides a kind of blood fat reducing preparation containing xylo-oligosaccharide, is by the raw material system of following weight portion
Into：Hawthorn 11-16 parts, avenabeta glucosan 9-13 parts, L-arabinose 8-14 parts, gynostemma pentaphylla 7-12 parts, Momordica grosvenori 6-10
Part, root of kudzu vine 5-9 parts, mulberry leaf 6-10 parts, xylo-oligosaccharide powder 5-10 parts, lotus leaf 4-8 parts, yam flour 3-7 parts, cassia seed 5-8 parts, hundred
Close 3-6 parts, functional Monascus 2-6 parts.
Preferably, the blood fat reducing preparation containing xylo-oligosaccharide, is made up of the raw material of following weight portion：
14 parts of hawthorn, 12 parts of avenabeta glucosan, 11 parts of L-arabinose, 10 parts of gynostemma pentaphylla, 9 parts of Momordica grosvenori, the root of kudzu vine 8
Part, 8 parts of mulberry leaf, 8 parts of xylo-oligosaccharide, 7 parts of lotus leaf, 6 parts of Chinese yam, 5 parts of cassia seed, 4 parts of lily, 3 parts of functional Monascus.
Preferably, the blood fat reducing preparation containing xylo-oligosaccharide, is made up of the raw material of following weight portion：
11 parts of hawthorn, 9 parts of avenabeta glucosan, 9 parts of L-arabinose, 10 parts of gynostemma pentaphylla, 6 parts of Momordica grosvenori, 5 parts of the root of kudzu vine,
7 parts of mulberry leaf, 10 parts of xylo-oligosaccharide, 5 parts of lotus leaf, 3 parts of Chinese yam, 7 parts of cassia seed, 6 parts of lily, 6 parts of functional Monascus.
It is a further object to provide the preparation method of the above-mentioned blood fat reducing preparation containing xylo-oligosaccharide, step is such as
Under：Hawthorn, gynostemma pentaphylla, Momordica grosvenori, the root of kudzu vine, mulberry leaf, lotus leaf, Chinese yam, cassia seed, lily are taken, is mixed, crushed, soaked, returned
Stream is extracted, and filters to obtain extract solution, and extract solution is concentrated, is spray-dried to obtain extract；By extract and avenabeta glucosan, L- I
Uncle's sugar, xylo-oligosaccharide and functional Monascus mix in proportion, mix, and obtain final product.
Preferably, the crushing mesh number is 20-30 mesh；
Preferably, the water that adds water and hawthorn, gynostemma pentaphylla, Momordica grosvenori, the root of kudzu vine, mulberry leaf, lotus leaf, Chinese yam, cassia seed, lily
The mass ratio for smashing mixture is 5-7:1, soak time is 30-60min；
Preferably, the refluxing extraction temperature is 80 DEG C, and extraction time is 30-40min.
Blood fat reducing health products containing xylo-oligosaccharide of the invention, the pharmacology and drug effect of each raw material are as follows in formula：
1) the hypolipidemic activity material in hawthorn is including general flavone, triterpenic acid, phytosterol, pectin pentasaccharides etc., by carrying
The expression of 7 α of high cholesterol-hydroxylase, suppresses the activity of cholesterol acyltransferase, increases LDL receptor level,
Regulate and control the mechanism of various lipid metabolism enzymes so as to adjust blood lipid level.
2) L-arabinose can effectively suppress the activity of human small intestine's mucous membrane invertase, and then prevent human body from dividing sucrose
Solution absorbs；Can also effectively control blood sugar and reduce the accumulation of fat, there are the diseases such as prevention high fat of blood, hyperglycaemia, obesity and hypertension
Disease effect.
3) Herb Gynostemmae Pentaphylli extract promotes the decomposition of cholesterol by the synthesis for promoting liver bile sour, accelerates cholesterol
Metabolism is so as to play a part of reduction blood fat.
4) Momordica grosvenori contains the medicinal ingredients such as mogroside, several amino acids and vitamin, and Momordica grosvenori is also called sweet taste
Element, widely uses, frequently as overweight people and the alternative sugar of diabetic because its sugariness is high, heat is low as sweetener.
5) Effective Fractions Depressing Blood-lipids are mainly isoflavonoid in the root of kudzu vine, and Puerarin has significant reducing blood lipid to make
With can effectively prevent and control the generation of atherosclerosis.
6) mulberry leaf contain a kind of unexistent alkaloid 1- deoxidations open country mycin " DNJ " of other animals and plants, can suppress invertase,
The sweet sugar of maltose, a- glucose, the decomposition of a- amylase, can stimulate insulin secretion, and reduce insulin decomposition rate.This
Outward, GABA, mulberry leaf polysaccharide, phenols and various the essential trace elements of the human bodys are rich in mulberry leaf, thus with drop blood
The effects such as fat, hypotensive, beauty.
Flavonoid substance in kudzu root extract is combined with DNJ in mulberry-leaf extract, can form a kind of new thing
Matter --- the clear sugar element of pancreas is washed, with the effect such as reducing blood lipid, blood sugar, anti-inflammatory, the synergy of reducing blood lipid is reached.
7) containing abundant dietary fiber in oat, wherein beta glucan has notable lowering blood-fat and reducing weight effect；Oat β-Portugal
Glycan can also promote Bifidobacterium and lactobacter growth as prebiotics, reduce Escherichia coli quantity.Lactobacillus strains can lead to
Cross hydrolysis small intestine in congugated bile acids constraint large intestine in deoxidation bile acid, suppressed with this bile acid intestines liver circulate in again
Absorb, so as to reach the effect of norcholesterol.
8) functional low polyxylose is a kind of oligosaccharide with prebiotic meta function.Xylo-oligosaccharide is to Bifidobacterium, lactic acid
The probiotics such as bacterium have high selectivity cultivation effect, there is obvious suppression to pathogens such as Escherichia coli, enterococcus, clostridium
Make and use.Bacillus acidi lactici and Bifidobacterium are finally reached the effect for reducing cholesterol by changing enteric microorganism species and flora
Really；Bifidobacterium has the physiology work(for reducing the aspects such as body's cholesterol, regulating intestinal canal flora, antitumor and delaying human body caducity
Energy.Probiotics suppress lipid synthesis, probiotics in growth course can using carbohydrate generate SCFA and
Its esters, especially propionate, can suppress the synthesis of aliphatic acid and cholesterol.Xylo-oligosaccharide can also strengthen Intestinal motility,
Promote fat metabolism, increase the absorption of mineral matter and trace element, improve intestine microenvironment, strengthen immunity of organisms.
Avenabeta glucosan and xylo-oligosaccharide can stimulate the propagation of beneficial bacterium in enteron aisle, suppress the growth of harmful bacteria, two
Person is simultaneously edible can to reach synergy, can promote a large amount of procreations of the probiotics in enteron aisle, and regulating intestinal canal Bacterial community is disorderly
Disorderly, be conducive to lowering influence of the hypolipidemic food congeneric drug to gut flora, further reduce body's cholesterol, reduce blood high
The generation of fat disease, improves body immunity, helps human body to get well level.
9) main chemical compositions of lotus leaf have lotus leaf alkaloid, lotus flavone, citric acid, oxalic acid etc., and lotus leaf has diuresis
Defaecation, logical intestines poison, lipid-loweringing oil removing, clear heat are antipyretic etc. to be acted on, and can substantially reduce triglyceride and cholesterol level in serum, is had
Adjust the health-care effect of blood fat.
10) Chinese yam has the effect of the puckery essence of engender liquid and benefic lung, tonifying spleen nourishing the stomach, kidney tonifying, for spleen eating less, loose stool diarrhoea, white
With diseases such as very few, diabetes.Chinese yam polysaccharide becomes apparent to hypoglycemic, blood fat effect.The anthraquinone component that cassia seed contains is about
1.2%, anthraquinone component is one of main component of cassia seed reducing blood lipid, cassia seeds protein be also cassia seed reducing blood lipid into
Point.
11) polysaccharide has reducing blood lipid, hypoglycemic, immune, antitumor, the anti-ageing effect of waiting for a long time of promotion, and toxic and side effect is minimum.
Polysaccharide reducing blood lipid is the hepato-enteric circulation by suppressing cholesterol biosynthesis, blocking cholesterol, so as to reduce cholesterol level in blood plasma；
Polysaccharide can also be by regulating and controlling Adipocyte Differentiation, suppressing the active of fatty acid decomposition relevant enzyme, promotion fatty acid oxidation, removing
Unnecessary free radical anti-lipid peroxidation realizes effect for reducing blood fat in vivo.Contain polysaccharide in radix polygonati officinalis and lily in raw materials used
Constituents.
12) functional Monascus are containing the plurality of active ingredients such as Monacolin K (Lovastatin), with high nutrition, health care,
Medical value, is a kind of natural, safe and effective health food, pharmaceutical raw material, tool without citrinin, without any side effects
There is regulation blood fat, reduce cholesterol, hypotensive, the hypoglycemic and antifatigue effect that gives protection against cancer.Lovastatin in functional Monascus
Liver is mainly acted on, the rate-limiting enzyme hydroxyl first glutaryl coenzyme A during cholesterol biosynthesis can be competitively suppressed in vivo
Reductase, so that the synthesis of cholesterol is reduced, can also synthesize LDL receptor increases, and makes cholesterolemia and low
Density lipoprotein-cholesterol level reduction, moreover it is possible to reduce serum triglyceride level and increase blood high density lipoprotein level plain boiled water
It is flat.
Immunity of organisms, pre- is improved preparing it is also another object of the present invention to provide the blood fat reducing preparation containing xylo-oligosaccharide
Application in anti-and auxiliary treatment hyperlipemia health products or medicine.
The health products or medicine, can also include conventional adjunct ingredient, such as magnesium stearate, sodium carboxymethylcellulose,
Silica, talcum powder, polyethylene glycol, microcrystalline cellulose etc.；The health products or medicine can be made into liquid electuary, pulvis, piece
The regular dosage form such as agent or capsule.
Because oral formulations enter enteron aisle, and enteric bacteria has material impact to traditional Chinese medicine ingredients effect.The present invention passes through
Scientific compatibility, selects the Chinese medicinal material of several integration of drinking and medicinal herbs to coordinate the oligosaccharides such as xylo-oligosaccharide, is made and makees with reduction blood fat
Preparation, wherein, the oligosaccharides such as xylo-oligosaccharide of addition gives full play to bifidus factor effect, can dramatically increase enteron aisle benefit
Raw Microflora, coordinating has reducing blood lipid, the integration of drinking and medicinal herbs Chinese medicine of enhance immunity, mitigates influence of the Chinese medicine to gut flora,
So as to realize that medicinal material and probiotics cooperatively play the effect of its reducing blood lipid.
It is in good taste that the present invention prepares blood fat reducing preparation, has no toxic side effect, and raw material sources enrich, and preparation method is simple,
Can be produced on a large scale, with preferable economic benefit and social benefit.
Specific embodiment
Further detailed description, but embodiments of the present invention not limited to this are done to the present invention with reference to embodiment.
Embodiment 1 prepares the auxiliary blood fat reducing health products containing xylo-oligosaccharide
It is formulated and is：14 parts of hawthorn, 12 parts of avenabeta glucosan, 11 parts of L-arabinose, 10 parts of gynostemma pentaphylla, 9 parts of Momordica grosvenori,
8 parts of the root of kudzu vine, 8 parts of mulberry leaf, 8 parts of xylo-oligosaccharide powder, 7 parts of lotus leaf, 6 parts of yam flour, 5 parts of cassia seed, 4 parts of lily, functional Monascus 3
Part.
Hawthorn, gynostemma pentaphylla, Momordica grosvenori, the root of kudzu vine, mulberry leaf, lotus leaf, Chinese yam, cassia seed, lily are taken, is mixed, crushed, add water leaching
Bubble, refluxing extraction filters to obtain extract solution, and extract solution is concentrated, is spray-dried to obtain extract；By extract and avenabeta glucosan,
L-arabinose, xylo-oligosaccharide and functional Monascus mix in proportion, mix, and obtain final product.
Wherein, the crushing mesh number is 20-30 mesh；The water that adds water and hawthorn, gynostemma pentaphylla, Momordica grosvenori, the root of kudzu vine, mulberry leaf, lotus
Leaf, Chinese yam, cassia seed, the mass ratio of the smashing mixture of lily are 5-7:1, soak time is 30-60min；The backflow is carried
Temperature is taken for 80 DEG C, extraction time is 30-40min.
Liquid electuary is made according to a conventional method, it is packed.
Embodiment 2
11 parts of hawthorn, 9 parts of avenabeta glucosan, 9 parts of L-arabinose, 10 parts of gynostemma pentaphylla, 6 parts of Momordica grosvenori, 5 parts of the root of kudzu vine,
7 parts of mulberry leaf, 10 parts of xylo-oligosaccharide, 5 parts of lotus leaf, 3 parts of Chinese yam, 7 parts of cassia seed, 6 parts of lily, 6 parts of functional Monascus.
Hawthorn, gynostemma pentaphylla, Momordica grosvenori, the root of kudzu vine, mulberry leaf, lotus leaf, Chinese yam, cassia seed, lily are taken, is mixed, crushed, add water leaching
Bubble, refluxing extraction filters to obtain extract solution, and extract solution is concentrated, is spray-dried to obtain extract；By extract and avenabeta glucosan,
L-arabinose, xylo-oligosaccharide and functional Monascus mix in proportion, mix, and obtain final product.
Wherein, the crushing mesh number is 20-30 mesh；The water that adds water and hawthorn, gynostemma pentaphylla, Momordica grosvenori, the root of kudzu vine, mulberry leaf, lotus
Leaf, Chinese yam, cassia seed, the mass ratio of the smashing mixture of lily are 5-7:1, soak time is 30-60min；The backflow is carried
Temperature is taken for 80 DEG C, extraction time is 30-40min.
Embodiment 3
12 parts of hawthorn, 8 parts of avenabeta glucosan, 10 parts of L-arabinose, 7 parts of gynostemma pentaphylla, 6 parts of Momordica grosvenori, 5 parts of the root of kudzu vine,
6 parts of mulberry leaf, 9 parts of xylo-oligosaccharide, 6 parts of lotus leaf, 4 parts of Chinese yam, 8 parts of cassia seed, 6 parts of lily, 8 parts of functional Monascus.
Hawthorn, gynostemma pentaphylla, Momordica grosvenori, the root of kudzu vine, mulberry leaf, lotus leaf, Chinese yam, cassia seed, lily are taken, is mixed, crushed, add water leaching
Bubble, refluxing extraction filters to obtain extract solution, and extract solution is concentrated, is spray-dried to obtain extract；By extract and avenabeta glucosan,
L-arabinose, xylo-oligosaccharide and functional Monascus mix in proportion, mix, and obtain final product.
Wherein, the crushing mesh number is 20-30 mesh；The water that adds water and hawthorn, gynostemma pentaphylla, Momordica grosvenori, the root of kudzu vine, mulberry leaf, lotus
Leaf, Chinese yam, cassia seed, the mass ratio of the smashing mixture of lily are 5-7:1, soak time is 30-60min；The backflow is carried
Temperature is taken for 80 DEG C, extraction time is 30-40min.
Comparative example 1
Preparation method replaces with the Radix Astragali with embodiment 1, difference in the root of kudzu vine, and cassia seed replaces with Semen Cuscutae.
Comparative example 2
With embodiment 1, difference is without L-arabinose, xylo-oligosaccharide to preparation method.
The blood fat reducing preparation of experimental example 1 adjusts blood fat zoopery
Ablactation rat body weight 60-80g after taking-up is raw 4 weeks, every group 10, totally 50, while being formulated 10 times using embodiment 1
Dosage group and embodiment 1, comparative example 1-2 dosage groups and blank control group, use deionized water sample dissolution, and oral gavage gives to be received
Examination animal, gavage amount is 1mL/100g, once a day, is fed 4 weeks.
Toxicity test result：Surrounding is observed after gastric infusion, does not find that experimental animal is dead, composition urgency of the invention
Property toxicity is low；Indices are determined, observation and measure project include such as outward appearance Signs and behavioral activity, secretion, fecal character,
The conventional index and biochemical indicator of blood, the content such as system postmortem and organ coefficient and histological examination, as a result show：With difference
Dosage gives rat continuous oral, on the food-intake and body weight increase of rat without influence, does not find obvious poison to hepatic and renal function
Property effect, blood routine, blood biochemistry, urine biochemistry and marrow piece etc. are showed no and are significantly affected.
Meanwhile, experiment is detected after terminating to each group rat blood serum triglycerides TG concentration (mmol/L, M ± SD), is tied
Fruit is shown in Table 1.
Table 1
| Group | TG concentration |
| Control group | 1.75±0.24 |
| The dosage group of embodiment 1 | 1.22±0.13 |
| The high dose group of embodiment 1 | 1.08±0.28 |
| The dosage group of comparative example 1 | 1.59±0.32 |
| The dosage group of comparative example 2 | 1.53±0.17 |
From table 1, the lipid-lowering effect of embodiment 1 is much better than comparative example 1 and comparative example 2.
Each group rat phagocyte phagocytic function after experiment is influenceed, 2 are the results are shown in Table.
Table 2
| Group | Phagocytic rate (%) |
| Control group | 31.75±8.24 |
| The dosage group of embodiment 1 | 42.52±5.19 |
| The high dose group of embodiment 1 | 46.48±7.24 |
| The dosage group of comparative example 1 | 38.42±4.57 |
| The dosage group of comparative example 2 | 34.25±5.24 |
From table 2, embodiment 1 is remarkably improved rat macrophage phagocytic function, and effect is much better than comparative example 1 and right
Ratio 2, so as to prove that invention formulation can significantly increase rat immunity power.
The human trial of experimental example 2
When taking, dissolved with warm water and taken after mixing it with water.
Treatment method：Disabled using the related medicine of preceding all reducing blood lipid, the reducing blood lipid of embodiment 1 of being taken after mixing it with water with warm water
Electuary, 2 times a day, and the i.e. morning and evening is each once, 1 bag every time (every bag of 10g), is within three weeks a course for the treatment of.
Outcome measure and clinical data:
Confirmed through the edible personnel's data of 150 clinics, wherein overweight people 61, partially fat 46, overweight 21, normal type
Person 16, inclined lean body mass person 6 is (according to constitutional index (BMI)=body weight (kilogram)/height (rice)2, Chinese Industrial Standards (CIS)：It is partially thin：≤
18.5；Normally：18.5-23.9；It is overweight：≥24；It is partially fat：24~27.9；It is fat：>=28), the age is between 25-68 Sui.
Therapeutic evaluation：
The normal value of Healthy Weight Pyramid T-CHOL value, should be below 200 milligrams.According to the difference at age, if super
Following standard value is crossed, can be considered that blood fat increases.20-25 Sui:120mg/dL；26-29 Sui:140mg/dL；30-39 Sui:150mg/
dL；40-49 Sui:160mg/dL；More than 50 years old:190mg/dL.
It is effective：After taking three courses for the treatment of, total cholesterol level is substantially reduced and reaches normal level, and one is observed after deactivation
Week, T-CHOL value is in normal range (NR).
Effectively：After taking three courses for the treatment of, T-CHOL value is substantially reduced, and is observed one week after deactivation, total cholesterol level base
This is not raised.
It is invalid：After taking three courses for the treatment of, T-CHOL value is not changed in substantially.
Treatment results：In 150 patients, effective 126, effective 16, invalid 8, obvious effective rate 84.0%, total effective rate
94.6%.Toxic and side effect is not found after taking, mouthfeel patient be easily accepted by.
Clinical typical case data：
Case 1：Mrs Li, 35 one full year of life, height 161cm, 74 kilograms of body weight, BMI values are 28.55, belong to overweight people, are taken
Preceding T-CHOL value is 6.54mmol/L, and after three courses for the treatment of are edible, T-CHOL value is reduced to normal level after testing.
Case 2：Mr. Yang, 47 one full year of life, height 167cm, 89.5 kilograms of body weight, BMI values are 32.09, belong to overweight people, are taken
It is 6.82mmol/L with preceding T-CHOL value, after three courses for the treatment of are taken, T-CHOL value is down to 6.03mmol/L after testing.
Case 3：Mrs Liu, 62 one full year of life, height 157cm, 68 jin of body weight, BMI values are 27.59, belong to partially fat person, before taking
T-CHOL value is 5.86mmol/L, by after the taking of three courses for the treatment of, T-CHOL value is obviously improved to normal value.
Above-described embodiment is the present invention preferably implementation method, but embodiments of the present invention are not by above-described embodiment
Limitation, one of ordinary skill in the art should be understood that on the basis of technical scheme those skilled in the art need not
The various modifications or deformation made by paying creative work are still in protection scope of the present invention.
Claims (9)
1. a kind of blood fat reducing preparation containing xylo-oligosaccharide, it is characterised in that be made up of the raw material of following weight portion：Hawthorn 11-16
Part, avenabeta glucosan 9-13 parts, L-arabinose 8-14 parts, gynostemma pentaphylla 7-12 parts, Momordica grosvenori 6-10 parts, root of kudzu vine 5-9 parts, mulberry
Leaf 6-10 parts, xylo-oligosaccharide powder 5-10 parts, lotus leaf 4-8 parts, yam flour 3-7 parts, cassia seed 5-8 parts, lily 3-6 parts, feature
Red yeast rice 2-6 parts.
2. a kind of blood fat reducing preparation containing xylo-oligosaccharide as claimed in claim 1, it is characterised in that by the original of following weight portion
Material is made：
14 parts of hawthorn, 12 parts of avenabeta glucosan, 11 parts of L-arabinose, 10 parts of gynostemma pentaphylla, 9 parts of Momordica grosvenori, 8 parts of the root of kudzu vine, mulberry
8 parts of leaf, 8 parts of xylo-oligosaccharide, 7 parts of lotus leaf, 6 parts of Chinese yam, 5 parts of cassia seed, 4 parts of lily, 3 parts of functional Monascus.
3. a kind of blood fat reducing preparation containing xylo-oligosaccharide as claimed in claim 1, it is characterised in that by the original of following weight portion
Material is made：
11 parts of hawthorn, 9 parts of avenabeta glucosan, 9 parts of L-arabinose, 10 parts of gynostemma pentaphylla, 6 parts of Momordica grosvenori, 5 parts of the root of kudzu vine, mulberry leaf 7
Part, 10 parts of xylo-oligosaccharide, 5 parts of lotus leaf, 3 parts of Chinese yam, 7 parts of cassia seed, 6 parts of lily, 6 parts of functional Monascus.
4. the preparation method of the blood fat reducing preparation of xylo-oligosaccharide is contained as described in claim any one of 1-3, it is characterised in that step
It is as follows：Hawthorn, gynostemma pentaphylla, Momordica grosvenori, the root of kudzu vine, mulberry leaf, lotus leaf, Chinese yam, cassia seed, lily are taken, are mixed, crushed, soaked,
Refluxing extraction, filters to obtain extract solution, and extract solution is concentrated, is spray-dried to obtain extract；By extract and avenabeta glucosan, L- Ah
Draw uncle's sugar, xylo-oligosaccharide and functional Monascus to mix in proportion, mix, obtain final product.
5. preparation method as claimed in claim 4, it is characterised in that the crushing mesh number is 20-30 mesh.
6. preparation method as claimed in claim 4, it is characterised in that the water that adds water and hawthorn, gynostemma pentaphylla, Momordica grosvenori, the root of kudzu vine,
Mulberry leaf, lotus leaf, Chinese yam, cassia seed, the mass ratio of the smashing mixture of lily are 5-7:1, soak time is 30-60min.
7. preparation method as claimed in claim 4, it is characterised in that the refluxing extraction temperature is 80 DEG C, and the backflow is carried
The time is taken for 30-40min.
8. the blood fat reducing preparation containing xylo-oligosaccharide is preparing raising immunity of organisms, prevention as described in claim any one of 1-3
With the application in auxiliary treatment hyperlipemia health products or medicine.
9. health products as claimed in claim 8 or medicine, it is characterised in that in addition to active ingredient, also including conventional auxiliary material
Composition, selected from magnesium stearate, sodium carboxymethylcellulose, silica, talcum powder, polyethylene glycol or microcrystalline cellulose；The guarantor
Strong product or medicine are made liquid electuary, pulvis, tablet or capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611249047.7A CN106729092A (en) | 2016-12-29 | 2016-12-29 | A kind of blood fat reducing preparation containing xylo-oligosaccharide and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611249047.7A CN106729092A (en) | 2016-12-29 | 2016-12-29 | A kind of blood fat reducing preparation containing xylo-oligosaccharide and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106729092A true CN106729092A (en) | 2017-05-31 |
Family
ID=58928206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611249047.7A Pending CN106729092A (en) | 2016-12-29 | 2016-12-29 | A kind of blood fat reducing preparation containing xylo-oligosaccharide and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106729092A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109221898A (en) * | 2018-06-04 | 2019-01-18 | 山东龙力生物科技股份有限公司 | A kind of grain dust and its preparation method and application containing xylo-oligosaccharide |
| CN109275906A (en) * | 2017-07-21 | 2019-01-29 | 广州医宗植物化妆品有限公司 | The preparation method of one kind of multiple plant compounding anoretics |
| CN109770150A (en) * | 2019-03-29 | 2019-05-21 | 郑州新福瑞生物科技有限公司 | A kind of functional solid beverage and preparation method thereof improving microcirculation disorder |
| CN110237101A (en) * | 2019-06-25 | 2019-09-17 | 东北制药集团沈阳第一制药有限公司 | A kind of bacillus licheniformis and the composition of xylo-oligosaccharide and application thereof |
| CN111345467A (en) * | 2020-03-18 | 2020-06-30 | 西安市如优商贸有限责任公司 | Dietary supplement, formulation and use thereof |
| CN112315972A (en) * | 2020-09-11 | 2021-02-05 | 唐传生物科技（厦门）有限公司 | Composition for preparing intestinal tract |
| CN112516206A (en) * | 2020-12-24 | 2021-03-19 | 中国科学院城市环境研究所 | Composition for reducing high blood pressure, high blood sugar and high blood fat, traditional Chinese medicine preparation and application |
| CN114190548A (en) * | 2021-11-24 | 2022-03-18 | 重庆万源佳药业有限公司 | Microecological extract with arteriosclerosis intervention function and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101450128A (en) * | 2007-11-28 | 2009-06-10 | 天津太平洋制药有限公司 | Blood-fat reducing and health-preserving wine containing xylo-oligosaccharides and preparation method thereof |
| CN102614203A (en) * | 2012-03-05 | 2012-08-01 | 苏州先阔生物科技有限公司 | Xylo-oligosaccharide composition with effect of inhibiting alpha-glucosaccharase as well as application of xylo-oligosaccharide composition |
| CN102613369A (en) * | 2012-03-05 | 2012-08-01 | 苏州先阔生物科技有限公司 | Coffee with effect of reducing blood sugar and blood fat |
| CN103190659A (en) * | 2013-04-12 | 2013-07-10 | 康美药业股份有限公司 | Plant beverage with pressure-drop, lipid-reducing, and hypoglycemic effects as well as preparation method and application thereof |
| CN103461980A (en) * | 2012-06-08 | 2013-12-25 | 苏州法莫生物技术有限公司 | Health food with function of adjusting blood fat |
-
2016
- 2016-12-29 CN CN201611249047.7A patent/CN106729092A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101450128A (en) * | 2007-11-28 | 2009-06-10 | 天津太平洋制药有限公司 | Blood-fat reducing and health-preserving wine containing xylo-oligosaccharides and preparation method thereof |
| CN102614203A (en) * | 2012-03-05 | 2012-08-01 | 苏州先阔生物科技有限公司 | Xylo-oligosaccharide composition with effect of inhibiting alpha-glucosaccharase as well as application of xylo-oligosaccharide composition |
| CN102613369A (en) * | 2012-03-05 | 2012-08-01 | 苏州先阔生物科技有限公司 | Coffee with effect of reducing blood sugar and blood fat |
| CN103461980A (en) * | 2012-06-08 | 2013-12-25 | 苏州法莫生物技术有限公司 | Health food with function of adjusting blood fat |
| CN103190659A (en) * | 2013-04-12 | 2013-07-10 | 康美药业股份有限公司 | Plant beverage with pressure-drop, lipid-reducing, and hypoglycemic effects as well as preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 邢连喜;蔺小平;常锋;徐增康;刘建书;: "脂糖泰胶囊辅助降血脂功能的实验研究", 陕西中医 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109275906A (en) * | 2017-07-21 | 2019-01-29 | 广州医宗植物化妆品有限公司 | The preparation method of one kind of multiple plant compounding anoretics |
| CN109221898A (en) * | 2018-06-04 | 2019-01-18 | 山东龙力生物科技股份有限公司 | A kind of grain dust and its preparation method and application containing xylo-oligosaccharide |
| CN109770150A (en) * | 2019-03-29 | 2019-05-21 | 郑州新福瑞生物科技有限公司 | A kind of functional solid beverage and preparation method thereof improving microcirculation disorder |
| CN110237101A (en) * | 2019-06-25 | 2019-09-17 | 东北制药集团沈阳第一制药有限公司 | A kind of bacillus licheniformis and the composition of xylo-oligosaccharide and application thereof |
| CN110237101B (en) * | 2019-06-25 | 2021-04-27 | 东北制药集团沈阳第一制药有限公司 | Composition of bacillus licheniformis and xylo-oligosaccharide and application thereof |
| CN111345467A (en) * | 2020-03-18 | 2020-06-30 | 西安市如优商贸有限责任公司 | Dietary supplement, formulation and use thereof |
| CN112315972A (en) * | 2020-09-11 | 2021-02-05 | 唐传生物科技（厦门）有限公司 | Composition for preparing intestinal tract |
| CN112315972B (en) * | 2020-09-11 | 2022-03-18 | 唐传生物科技（厦门）有限公司 | Composition for preparing intestinal tract |
| CN112516206A (en) * | 2020-12-24 | 2021-03-19 | 中国科学院城市环境研究所 | Composition for reducing high blood pressure, high blood sugar and high blood fat, traditional Chinese medicine preparation and application |
| CN114190548A (en) * | 2021-11-24 | 2022-03-18 | 重庆万源佳药业有限公司 | Microecological extract with arteriosclerosis intervention function and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106729092A (en) | A kind of blood fat reducing preparation containing xylo-oligosaccharide and its preparation method and application | |
| CN102406860B (en) | Composition for preventing and treating diabetes, and preparation method and use thereof | |
| CN102919836B (en) | Health-care product capable of reducing blood glucose, releasing pressure, reducing lipid, relaxing bowel, beautifying, losing weight and resisting fatigue and production process thereof | |
| CN103099089B (en) | Health-care product for reducing blood sugar and blood pressure, relaxing bowels, losing weight, resisting fatigue and improving sexual function and production technology thereof | |
| CN104982928B (en) | A kind of japanese yew fruit health care ferment and preparation method thereof | |
| CN115120683B (en) | Raw material composition, traditional Chinese medicine fermented product, and preparation method and application thereof | |
| CN106072578A (en) | There is the enhancing enzyme composition of immune function of human body, effervescent tablet and preparation method | |
| CN101579120A (en) | Nutritional food with weight-losing function and preparation method thereof | |
| CN108392519A (en) | A kind of hypoglycemic composition and its preparation and application | |
| CN106901118A (en) | Solid beverage with auxiliary hyperglycemic effect and preparation method thereof | |
| CN104799286B (en) | Composition for improving immunity and preparation method of composition | |
| CN101836725A (en) | Application of red rice residue product in preparing health-care food for lowering blood fat | |
| CN114259044A (en) | Semen cassiae and fructus cannabis compound fermentation product, functional fruit and vegetable enzyme jelly and preparation method of fruit and vegetable enzyme jelly | |
| CN109528814A (en) | A kind of probiotics and its preparation method and application of lactobacillus-fermented Radix Astragali | |
| CN105661515A (en) | Enzyme lozenges for three-hypers and preparation method thereof | |
| CN109123351A (en) | A kind of special doctor's food and preparation method with hyperglycemia population generation meal regulatory function | |
| CN104381991A (en) | Ganoderma lucidum sporoderm-broken spore powder capsule and preparation method thereof | |
| CN112516206A (en) | Composition for reducing high blood pressure, high blood sugar and high blood fat, traditional Chinese medicine preparation and application | |
| CN1403017A (en) | Selenium-rich konjaku-green tea health food | |
| CN106177432A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja, Folium Mori, green tea and Rhizoma Polygonati Odorati | |
| CN107375466A (en) | A kind of medicine-food two-purpose zymotic fluid with hypolipemic function and preparation method thereof | |
| CN103690819A (en) | Traditional Chinese medicinal composition capable of preventing and treating cardiovascular and cerebrovascular diseases and with weight reducing function | |
| CN103920140B (en) | A kind of people is with blood sugar lowering Weight-reducing and lipid-lowering compound preparation | |
| CN111387345A (en) | Compound polysaccharide composition and preparation method thereof | |
| CN105176773A (en) | Pumpkin wine capable of adjusting blood glucose and making method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170531 |
|
| RJ01 | Rejection of invention patent application after publication |